文献速递乳腺癌

基于医院乳腺癌女性队列评估胚系基因检测标准

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
PubMed 文献 · J Clin Oncol · 2020-03-03

该研究在2000至2016年一家三级癌症中心的乳腺癌登记队列中,评估9个乳腺癌易感基因的胚系致病变异,并比较NCCN遗传性癌症检测标准与对所有女性检测策略的灵敏度与特异度。结果显示NCCN标准灵敏度为70%(9基因)和87%(BRCA1/2),特异度53%;将标准扩展至所有≤65岁确诊女性可使灵敏度分别超过90%和98%。

要点

  • NCCN标准对9个易感基因的灵敏度为70%,对BRCA1/2为87%,特异度53%。
  • 未满足NCCN标准的2035例中,仅0.7%携带BRCA1/2致病变异。
  • 将NCCN标准扩展至所有≤65岁确诊女性,9基因灵敏度超90%,BRCA1/2超98%。

核心结论

  • 相当比例的乳腺癌胚系致病变异携带者不符合NCCN检测标准。
  • 将NCCN标准扩展至所有≤65岁确诊女性可提高选择标准灵敏度,且无需检测所有乳腺癌女性。

研究设计与样本

  • 研究纳入2000至2016年一家三级癌症中心乳腺癌登记队列的女性。
  • 评估9个乳腺癌易感基因(ATM、BRCA1、BRCA2、CDH1、CHEK2、NF1、PALB2、PTEN、TP53)的胚系致病变异。
  • 比较NCCN遗传性癌症检测标准与对所有女性检测(美国乳腺外科医师学会推荐)的表现。

主要发现

  • 3907例女性中,1872例(47.9%)符合NCCN标准,其9个易感基因致病变异携带率高于不符合者(9.0% vs 3.5%;P < .001)。
  • 不符合NCCN标准的2035例中,14例(0.7%)携带BRCA1或BRCA2致病变异。
  • NCCN标准对9个易感基因的灵敏度为70%,对BRCA1和BRCA2为87%,特异度为53%。
  • 将NCCN标准扩展至所有≤65岁确诊乳腺癌女性,对9个易感基因灵敏度>90%,对BRCA1和BRCA2灵敏度>98%。

关键数值与推荐

  • NCCN标准灵敏度:9基因70%,BRCA1/2 87%;特异度53%。
  • 扩展标准(所有≤65岁确诊女性):9基因灵敏度>90%,BRCA1/2灵敏度>98%。

临床怎么用

  • 当前NCCN标准会漏检部分胚系致病变异携带者,尤其BRCA1/2以外基因。
  • 将检测标准放宽至所有≤65岁确诊乳腺癌女性,可在不检测所有患者的前提下提高灵敏度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the sensitivity and specificity of genetic testing criteria for the detection of germline pathogenic variants in women with breast cancer. MATERIALS AND METHODS: Women with breast cancer enrolled in a breast cancer registry at a tertiary cancer center between 2000 and 2016 were evaluated for germline pathogenic variants in 9 breast cancer predisposition genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, and TP53). The performance of the National Comprehensive Cancer Network (NCCN) hereditary cancer testing criteria was evaluated relative to testing of all women as recommended by the American Society of Breast Surgeons. RESULTS: Of 3,907 women, 1,872 (47.9%) meeting NCCN criteria were more likely to carry a pathogenic variant in 9 predisposition genes compared with women not meeting criteria (9.0% v 3.5%; P < .001). Of those not meeting criteria (n = 2,035), 14 (0.7%) had pathogenic variants in BRCA1 or BRCA2. The sensitivity of NCCN criteria was 70% for 9 predisposition genes and 87% for BRCA1 and BRCA2, with a specificity of 53%. Expansion of the NCCN criteria to include all women diagnosed with breast cancer at ≤ 65 years of age achieved > 90% sensitivity for the 9 predisposition genes and > 98% sensitivity for BRCA1 and BRCA2. CONCLUSION: A substantial proportion of women with breast cancer carrying germline pathogenic variants in predisposition genes do not qualify for testing by NCCN criteria. Expansion of NCCN criteria to include all women diagnosed at ≤ 65 years of age improves the sensitivity of the selection criteria without requiring testing of all women with breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yadav S, Hu C, Hart SN, et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. J Clin Oncol. 2020. PMID: 32125938. doi:10.1200/JCO.19.02190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。